SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020, and provided a corporate update. Recent highlights include:
News Ticker
- [ September 28, 2023 ] TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting Los Angeles Biotech News
- [ September 28, 2023 ] Alfred Mann Foundation Rebrands as huMannity Medtec, Unveiling a Bold, Future-Focused Identity Los Angeles Biotech News
- [ September 28, 2023 ] Medical Laboratory Scientist – VIR Healthway – Santa Monica, CA Los Angeles Biotech Jobs
- [ September 28, 2023 ] New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint® Los Angeles Biotech News
- [ September 28, 2023 ] Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
